Topical pimecrolimus: A review of its clinical potential in the management of atopic dermatitis

Drugs

Volumn 62, Issue 5, 2002, Pages 817-840

  Wellington, Keri ^a   Jarvis, Blair ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

ASM 981; Atopic dermatitis; Atopic eczema; Pharmacodynamics; Pharmacokinetics; Pimecrolimus; SDZ ASM 981; Therapeutic use

Indexed keywords

PIMECROLIMUS;

ADOLESCENT; ADULT; ATOPIC DERMATITIS; BURN; CHILD; CLINICAL TRIAL; DOSE CALCULATION; DRUG ABSORPTION; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG MECHANISM; DRUG METABOLISM; DRUG TOLERABILITY; GROUPS BY AGE; HUMAN; INFANT; NONHUMAN; PHARMACODYNAMICS; REVIEW; VIRUS INFECTION;

EID: 0036252948     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-200262050-00007     Document Type: Review

References (79)

1. The prevalence of childhood atopic dermatitis in a general population
2. Atopic dermatitis: How to recognize, how to treat
3. Pathophysiologic mechanisms in atopic dermatitis
4. A novel anti-inflammatory drug, SDZ ASM 981, for the treatment of skin diseases: In vitro pharmacology
5. Ascomycin macrolactam derivative SDZ ASM 981 inhibits the release of granule-associated mediators and of newly synthesized cytokines in RBL 2H3 mast cells in an immunophilin-dependent manner
6. T cells involved in psoriasis vulgaris belong to the Th1 subset
7. Psoriasis
8. New drugs in the treatment of psoriasis
9. Novel immunomodulators for topical skin disease therapy
10. Allergy and the skin. II. Contact and atopic eczema
11. Tacrolimus and pimecrolimus: From clever prokaryotes to inhibiting calcineurin and treating atopic dermatitis
12. Pathogenic mechanisms: A rational basis for treatment
13. Allergen-induced inflammation and the role of immunoglobulin E (IgE)
14. Genetic linkage of childhood atopic dermatitis to psoriasis susceptibility loci
15. Ascomycins: Promising agents for the treatment of inflammatory skin diseases
16. Ascomycin derivatives and their use as immunosuppressive agents
17. SDZ ASM 981
18. Pimecrolimus cream 1%: A new development in nonsteroid topical treatment of inflammatory skin diseases
19. Pimecrolimus (Elidel, SDZ ASM 981) - Preclinical pharmacologic profile and skin selectivity
20. The new topical ascomycin derivative SDZ ASM 981 does not induce skin atrophy when applied to normal skin for 4 weeks: A randomized, double-blind controlled study
21. Good skin tolerability of SDZ ASM 981 cream
22. Skin biopsy analyses of psoriasis patients treated with pimecrolimus (SDZ ASM 981) confirms reversal to normal phenotype
23. The ascomycin macrolactam pimecrolimus (Elidel, SDZ ASM 981) is a potent inhibitor of mediator release from human dermal mast cells and peripheral blood basophils
24. A novel anti-inflammatory drug, SDZ ASM 981, for the topical and oral treatment of skin diseases: In vivo pharmacology
25. Pimecrolimus (Elidel, SDZ ASM 981), in contrast to cyclosporin A and tacrolimus, is highly effective in animal models of skin inflammation but has only low activity in models indicating immunosuppressive potential
26. SDZ ASM 981 oral shows activity against murine allergic contact dermatitis, different from FK 506 and cyclosporin A
27. Calcineurin inhibitors FK506 and SDZ ASM 981 alleviate the outcome of focal cerebral ischemic/reperfusion injury
28. SDZ ASM 981 potently inhibits the induction of coreceptors involved in the accessory cell-dependent activation of inflammation-mediating T cells
29. Atopic dermatitis-like symptoms in hypomagnesaemic hairless rats are prevented and inhibited by systemic or topical SDZ ASM 981
30. SDZ ASM 981 is the first non-steroid that suppresses established nickel contact dermatitis elicited by allergen challenge
31. Low blood concentrations of pimecrolimus (Elidel, SDZ ASM 981) after topical treatment of adults with atopic dermatitis
32. Low systemic exposure after repeated topical application of pimecrolimus (Elidel, SDZ ASM 981) in patients with atopic dermatitis
33. First experience of topical SDZ ASM 981 in children with atopic dermatitis
34. Pimecrolimus (Elidel, SDZ ASM 981 cream 1%) blood levels are consistently low in children with extensive atopic eczema
35. Oral SDZ ASM 981: Pharmacokinetic profile in humans
36. Clinical experience with oral SDZ ASM 981 in psoriasis
37. Oral SDZ ASM 981: Pharmacokinetic profile in humans
38. SDZ ASM 981: An emerging safe and effective treatment for atopic dermatitis
39. Effectiveness of the ascomycin macrolactam SDZ ASM 981 in the topical treatment of atopic dermatitis
40. Pimecrolimus (SDZ ASM 981) cream reduces the need for corticosteroids in the long-term management of atopic dermatitis in adults
41. SDZ ASM 981 cream 1%: A new approach to long-term management of atopic dermatitis
42. Pimecrolimus (SDZ ASM 981) cream reduces the number of flares and the need for topical corticosteroids in children with atopic dermatitis: A 12-month, double-blind, controlled study
43. SDZ ASM 981 cream 1% is effective and safe in children and adolescents with atopic dermatitis
44. The benefit of pimecrolimus (Elidel, SDZ ASM 981) on quality of life in the treatment of pediatric atopic dermatitis: Results of two 6-week randomized double-blind vehicle-controlled clinical trials in the US
45. Pimecrolimus (Elidel, SDZ ASM 981) cream 1% is safe in the long-term management of atopic dermatitis
46. Pimecrolimus (Elidel, SDZ ASM 981) cream 1%: A new approach to long-term management of atopic dermatitis in infants 3 to 23 months of age
47. Pimecrolimus (Elidel, SDZ ASM 981) cream 1% is effective and safe in infants aged 3-23 months with atopic dermatitis
48. The eczema area and severity index (EASI): Assessment of reliability in atopic dermatitis
49. The novel ascomycin derivative SDZ ASM 981 is effective for psoriasis when used topically under occlusion
50. Oral SDZ ASM 981: Clinical safety, tolerability, and efficacy in patients with moderate to severe chronic plaque psoriasis
51. Pimecrolimus (Elidel, SDZ ASM 981) ointment is effective in psoriasis without occlusion
52. 1% SDZ ASM 981 cream effective in the treatment of chronic irritant hand dermatitis: A 6 week, randomised, double blind, vehicle controlled, single center study 2000
53. Diagnostic features of atopic dermatitis
54. Grading of the severity of atopic dermatitis
55. Eczema area and severity index (EASI): A new tool to evaluate atopic dermatitis
56. Atopic dermatitis: Current concepts support old therapies and spur new ones
57. Worldwide variations in the prevalence of symptoms of atopic eczema in the International Study of Asthma and Allergies in Childhood
58. Atopic dermatitis in infants and children: An update
59. Atopic dermatitis in infants and children
60. Clinical effects of diaper types on the skin of normal infants and infants with atopic dermatitis
61. Atopic dermatitis: The role of environmental and social factors, the European experience
62. Atopic dermatitis and the immune system: The role of superantigens and bacteria
63. Role of aeroallergens in atopic eczema: Proof of concept with the atopy patch test
64. The role of food in atopic eczema
65. Role of the early environment for expression of atopic dermatitis
66. Quality of life in atopic dermatitis
67. Role of social factors in atopic dermatitis: The US perspective
68. Old, new, and emerging therapies for atopic dermatitis
69. Itch in atopic dermatitis
70. Psychologic approach to atopic skin disease
71. Disease management of atopic dermatitis: A practice parameter
72. Staphylococcus aureus in the lesions of atopic dermatitis
73. Topical tacrolimus and pimecrolimus: Future directions
74. Safety of the new macrolide immunomodulators
75. Topical tacrolimus in the treatment of atopic dermatitis